secwatch.observer — SEC 8-K summary
======================================

Issuer:     Natera, Inc. (NTRA)
CIK:        0001604821
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001104659-25-046121
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Natera Q1 revenue $501.8M (+36.5% YoY); positive cash flow $23.2M
-----------------------------------------------------------------

- Total revenue $501.8M (+36.5% YoY); product revenue $500.0M (+37.1%).
- Gross margin 63.1% (up from 56.7%); tests processed 855,100 (+16.2%).
- Net loss $66.9M ($0.50 EPS) improved from $67.6M ($0.56) in prior year.
- Positive operating cash flow $23.2M; cash & investments $991.6M.
- Oncology test volume 167,700 (+46.1% YoY); CEO cites record Signatera growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604821/000110465925046121/0001104659-25-046121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604821/000110465925046121/tm2513945d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-046121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer